The U.S. Food and Drug Association (FDA) recently approved Retevmo® (selpercatinib) capsules. START Midwest, led by Nehal Lakhani, MD, PhD, researched the effectiveness of this therapy in thyroid and lung cancer patients whose tumors have a mutation or fusion in a specific gene. Retevmo® has now become the first FDA approved therapy for patients with these specific RET gene alterations. To learn more about Retevmo®, read here.
Cancer & Hematology Centers of Western Michigan (CHCWM) would like to congratulate those at START Midwest for their achievement. Part of the global START network, START Midwest provides our community first-ever access to experimental treatments and therapies. Located on the first floor of CHCWM’s East building, START Midwest offers a wide range of Phase I trials led by four of our CHC physicians; Dr. Nehal Lakhani, Dr. Manish Sharma, Dr. Sreenivasa Chandana and Dr. Timothy O’Rourke.
If you have questions or would like to learn more about our Phase I Clinical Trials, please call us at (616) 954-5554